Cargando…
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
L-DOPA therapy in Parkinson’s disease (PD) is limited due to emerging L-DOPA-induced dyskinesia. Research has identified abnormal dopamine release from serotonergic (5-HT) terminals contributing to this dyskinesia. Selective serotonin reuptake inhibitors (SSRIs) or 5-HT receptor (5-HTr) agonists can...
Autores principales: | Altwal, Feras, Padovan-Neto, Fernando E., Ritger, Alexandra, Steiner, Heinz, West, Anthony R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510243/ https://www.ncbi.nlm.nih.gov/pubmed/34641332 http://dx.doi.org/10.3390/molecules26195790 |
Ejemplares similares
-
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease
por: Altwal, Feras, et al.
Publicado: (2020) -
D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia
por: Florio, Ermanno, et al.
Publicado: (2022) -
L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission
por: Feyder, Michael, et al.
Publicado: (2011) -
Input Dependent Cell Assembly Dynamics in a Model of the Striatal Medium Spiny Neuron Network
por: Ponzi, Adam, et al.
Publicado: (2012) -
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
por: Rylander Ottosson, Daniella, et al.
Publicado: (2016)